Home » Market News » DirectorsTalk Highlights » Skinbiotherapeutics Plc: Probiotics to replace antibiotics in wound healing?
SkinBiotherapeutics Plc

Skinbiotherapeutics Plc: Probiotics to replace antibiotics in wound healing?

Did you know that bacteria have antibacterial properties? Its true.

We spoke to Dr Catherine O’neill CEO of Skinbiotix Plc (LON:SBTX) who said, ‘Its worth remembering that penicillin, one of the first antibiotics to be used medically, is derived from a mould. Micro-organisms make antibacterial compounds against each other. Against this background, the hope is that new antibiotics will be discovered in the human microbiome that will help in the fight against antibiotics resistance.’

In a world where antibiotic resistance is becoming a major problem, scientists race in search for alternatives. Could bacteria provide much-needed strategies to prevent life-threatening infections? The following article provides valuable insight into this and more: https://www.medicalnewstoday.com/articles/318765.php

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. The company platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.